Priming of blood neutrophils in children with cystic fibrosis: Correlation between functional and phenotypic expression of opsonin receptors before and after platelet-activating factor priming

Journal of Infectious Diseases

Volumn 179, Issue 1, 1999, Pages 151-162

  Witko Sarsat, Véronique ^a   Halbwachs Mecarelli, Lise ^b   Sermet Gaudelus, Isabelle ^b   Bessou, Gilles ^b   Lenoir, Gérard ^b   Allen, Robert C ^b   Descamps Latscha, Béatrice ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD16 ANTIGEN; CD32 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; LUMINOL; MYELOPEROXIDASE; OPSONIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THROMBOCYTE ACTIVATING FACTOR; ZYMOSAN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUMINESCENCE; LUNG INFECTION; MALE; NEUTROPHIL; PHAGOCYTE; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ADULT; BRONCHIAL DISEASES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; GENOTYPE; HUMANS; INFANT; INFLAMMATION MEDIATORS; MALE; NEUTROPHILS; PHENOTYPE; PLATELET ACTIVATING FACTOR; PSEUDOMONAS INFECTIONS; RECEPTORS, IMMUNOLOGIC; STAPHYLOCOCCAL INFECTIONS;

EID: 0032938086     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314532     Document Type: Article

References (49)

1. Boat TF, Welsh MJ, Beaudet AL. Cystic fibrosis. In: Scriver R, Beaudet AL, Ly WS, Valle D, eds. The metabolic basis of inherited disease, New York: McGraw-Hill, 1989:2649-80.
2. Nadel JA. Protease actions on airway secretions. Relevance to cystic fibrosis. Ann NY Acad Sci 1991;624:286-96.
3. Goldstein W, Döring G. Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis 1986;134:49-56.
4. Birrer P, McElvaney NG, Rudeberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994;150:207-13.
5. Noah TL, Black HR, Cheng PW, Wood RE. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 1997;175:638-47.
6. Suter S, Schaad UB, Roux-Lombard P, Girardin E, Grau G, Dayer JM. Relation between tumor necrosis factor-alpha and granulocyte elastase-alpha 1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis. Am Rev Respir Dis 1989;140:1640-4.
7. Witko-Sarsat V, Delacourt C, Rabier D, Bardet J, Nguyen AT, Descamps-Latscha B. Neutrophil-derived long-lived oxidants in cystic fibrosis sputum. Am J Respir Crit Care Med 1995;152:1910-6.
8. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-73.
9. Prince A. The CFTR advantage capitalizing on a quirk of fate. Nat Med 1998;4:663-4.
10. Khan TZ, Wagner JS, Bost T, Martinez J, Accurso FJ, Riches DWH. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-82.
11. Witko-Sarsat V, Allen RC, Paulais M, et al. Disturbed myeloperoxidase-dependent activity of neutrophils in cystic fibrosis homozygotes and heterozygotes, and its correction by amiloride. J Immunol 1996;157:2728-35.
12. Klebanoff SJ, Clark RA. The neutrophil: function and clinical disorders. Amsterdam: North-Holland, 1978.
13. Allen RC, Stevens DL. The circulating phagocyte reflects the in vivo state of immune defense. Curr Opin Infect Dis 1992;5:389-98.
14. Descamps-Latscha B, Golub RM, Nguyen AT, Feuillet-Fieux MN. Monoclonal antibodies against T cell differentiation antigens initiate stimulation of monocyte/macrophage oxidative metabolism. J Immunol 1993;131:2500-7.
15. Allen RC, Stjernholm RL, Steele RH. Evidence for the generation of an electronic excitation state(s) in human polymorphonuclear leukocytes and its participation in bactericidal activity. Biochem Biophys Res Commun 1972;47:679-84.
16. Babior BM, Kipnes RS, Curnutte JT. Biological defense mechanisms: the production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest 1973;52:741-4.
17. Allen RC, Yevitch SJ, Orth RW, Steele RH. The superoxide anion and singlet molecular oxygen: their role in the microbicidal activity of the polymorphonuclear leukocyte. Biochem Biophys Res Commun 1974;60:909-17.
18. Rosen H, Klebanoff SJ. Bactericidal activity of a superoxide anion generating system: a model for the polymorphonuclear leukocyte. J Exp Med 1979;149:27-39.
19. Stevens DL, Bryant AE, Huffman J, Thompson K, Allen RC. Analysis of circulating phagocyte activity measured by whole blood luminescence: correlation with clinical status. J Infect Dis 1994;170:1463-72.
20. Chatta GS, Price TH, Allen RC, Dale DC. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994;84:2923-8.
21. Allen RC, Stevens PR, Price TH, Chatta GS, Dale DC. In vivo effects of recombinant human granulocyte colony-stimulating factor on neutrophil oxidative functions in normal human volunteers. J Infect Dis 1997;175:1184-92.
22. Mearns MB. Cystic fibrosis: the first 50 years. A review of the clinical problems and their management. In: Dodge JA, Brock DJH, eds. Cystic fibrosis. New York: John Wiley and Sons, 1993:217-50.
23. Shwachman H, Kulczyki L. Long-term study of one hundred and five patients with cystic fibrosis. Am J Dis Child 1958;96:6-15.
24. Brasfield D, Hicks G, Seng-jaw S, Tiller RE. The chest roentgenogram in cystic fibrosis: a new scoring system. Pediatrics 1979;63:24-9.
25. Polgar G, Promadhat V. Pulmonary function testing in children: techniques and standards. Philadelphia: WB Saunders, 1971.
26. Puchelle E, Tournier JM, Zahm JM, Sadoul P. Rheology of sputum collected by a simple technique limiting salivary contamination. J Lab Clin Med 1984;103:347-53.
27. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan PD. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in cystic fibrosis. Pediatr Pneumol 1996;21:265-6.
28. Puchelle E, Beck G, Thevenin F. Quantitative bacteriology of sputum and bronchial secretions in patients with chronic bronchitis. Respiration 1977;34:220-31.
29. Allen RC. Phagocytic leukocyte oxidative activity and chemiluminescence: a kinetic approach to analysis. Methods Enzymol 1986;133:449-93.
30. Descamps-Latscha B, Golub RM, Nguyen AT, Feuillet-Fieux MN. Chemiluminescence in micro amounts of whole blood for investigation of the human phagocyte oxidative metabolism function. Ann Immunol 1982;133C:349-64.
31. Brown GE, Reiff J, Allen RC, Silver GM, Fink MP. Maintenance and down-regulation of primed neutrophil chemiluminescence activity in human whole blood. J Leukoc Biol 1997;62:837-44.
32. Ramsey BW, Wentz KR, Smith AL, et al. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. Am Rev Respir Dis 1991;144:331-7.
33. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995;310:1571-2.
34. Konstan MW, Byard PJ, Hoppel CL, Davies PB. Effect of high dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-54.
35. Brown R, Kelly FJ. Role of free radicals in the pathogenesis of cystic fibrosis. Thorax 1994;49:738-43.
36. Davies PB, Vargo K. Pulmonary abnormalities in obligate heterozygotes for cystic fibrosis. Thorax 1987;42:120-5.
37. Yoshimura K, Nakamura H, Trapnell BC, et al. Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. Nucleic Acids Res 1991;19:5417-23.
38. Rosenstein BJ. Genotype-phenotype correlations in cystic fibrosis. Lancet 1994;43:746-7.
39. Kuijpers TW, Tool AT, Van Der Schoot CE, et al. Membrane surface antigen expression on neutrophils: a reappraisal of the use of surface markers for neutrophil activation. Blood 1991;78:1105-11.
40. Berger M, Sorensen RU, Tosi MF, Dearborn DG, Döring G. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest 1989;84:1302-13.
41. Russel KJ, McRedmond J, Mukherji N, et al. Neutrophil adhesion molecule surface expression and responsiveness in cystic fibrosis. Am J Respir Crit Care Med 1998;157:756-61.
42. Shalit M, Von Allmen C, Atkins PC, Zweiman B. Platelet activating factor increases expression of complement receptors on human neutrophils. J Leukoc Biol 1988;44:212-7.
43. Ogle JD, Noel JG, Sramkoski RM, Ogle CK, Alexander JW. The effects of cytokines, platelet activating factor, and arachidonate metabolites on C3b receptor (CR1, CD35) expression and phagocytosis by neutrophils. Cytokine 1990;2:447-55.
44. Van Epps DE, Bender JG, Simpson SJ, Chenoweth DE. Relationship of chemotactic receptors for formyl peptide and C5a to CR1, CR3, and Fc receptors on human neutrophils. J Leukoc Biol 1990;47:519-27.
45. Allen RC. Role of oxygen in phagocyte microbicidal action. Environ Health Perspect 1994;102(suppl 10):201-8.
46. McColl SR, Beauseigle D, Gilbert C, Naccache PH. Priming of the human neutrophil respiratory burst by granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha involves regulation at a post-cell surface receptor level. Enhancement of the effect of agents which directly activate G proteins. J Immunol 1990;145:3047-53.
47. Brunkhorst BA, Strohmeier G, Lazzari K, et al. Differential roles of Fc gamma RII and Fc gamma RIII in immune complex stimulation of human neutrophils. J Biol Chem 1992;267:20659-66.
48. Edberg JC, Kimberly RP. Modulation of Fc gamma and complement receptor function by the glycosyl-phosphatidylinositol-anchored form of Fc gamma RIII. J Immunol 1994;152:5826-35.
49. Huizinga TW, Van Der Schoot CE, Jost C, et al. The PI-linked receptor FcRIII is released on stimulation of neutrophils. Nature 1988;333:667-9.